Risk Factors and Outcomes in Patients Treated in Neurocritical Care

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07052656

Acronym

EpiNIC

Enrollment

70000

Registered

2025-07-04

Start date

2010-01-01

Completion date

2024-12-31

Last updated

2025-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Brain Injuries, Acute Neurological Injury, Epilepsy, Intracerebral Hemorrhage, Ischemic Stroke, Meningitis, Neuro-intensive Care Unit Patients, Stroke, Acute, Subarachnoid Hemorrhage, Aneurysmal, Traumatic Brain Injury

Brief summary

The overall purpose of this epidemiologic research project is to provide a comprehensive exploration and analysis of critical elements within the neuro-intensive care process in Sweden. All aspects of intensive care management in critically ill patients with acute brain injury will be addressed. The analyses include description of patient characteristics, intensive care data, management and treatments, various aspects of short and long-term follow-up, mortality, regional- and sex-related differences. The long-term goal is to develop neuro-intensive care and management, to minimize in-hospital insults and secondary injuries, to improve diagnostics and follow-up, in order to reduce prolonged neurologic deficits and mortality in these patients.

Interventions

OTHERObservational study, participants are not assigned an intervention as part of the study.

Observational study, participants are not assigned an intervention as part of the study.

OTHERTransport modality

Transfer modality to tertiary centers

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* ICU admission 2010 to 2024 * Clinical diagnosis of subarachnoid hemorrhage, intracranial hemorrhage or ischemic brain injury, traumatic brain injury, epilepsy, meningitis, encefalititis or other brain injury diagnosis.

Design outcomes

Primary

Measure	Time frame	Description
Mortality	Up to two years	Mortality

Secondary

Measure	Time frame	Description
Morbidity	Up to two years	Neuropsychiatric diagnoses, depression/anxiety), longterm sick leave, loss of income as a proxy for quality of life

Other

Measure	Time frame	Description
DAOH90	90 days	Days alive and out of hospital
Complications	90 days	Rebleeding, secondary insults, cerebral infarctions

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026